合理用药
不良反应
新药前沿
药物治疗
关键字:
搜索栏目:
 首页 >> 合理用药 >> 药物治疗
青蒿琥酯-阿莫地喹疗法对恶性疟患者疗效不佳
作者:本站 时间:2010-11-15 点击:568 来源:Lancet Infectious Diseases
<P style="BACKGROUND: white; LINE-HEIGHT: 16.5pt"><SPAN style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">&nbsp;&nbsp; 英国学者的一项研究表明,由于其他青蒿素联合治疗(</SPAN><SPAN lang=EN-US style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; FONT-FAMILY: Arial">ACT</SPAN><SPAN style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">)更为有效,所以青蒿琥酯</SPAN><SPAN lang=EN-US style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; FONT-FAMILY: Arial">-</SPAN><SPAN style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">阿莫地喹疗法不应在缅甸使用,在此基础上添加单剂伯氨喹可显著降低恶性疟感染风险。该研究</SPAN><?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" /><st1:chsdate w:st="on" IsROCDate="False" IsLunarDate="False" Day="9" Month="9" Year="2010"><SPAN lang=EN-US style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; FONT-FAMILY: Arial">2010</SPAN><SPAN style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">年</SPAN><SPAN lang=EN-US style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; FONT-FAMILY: Arial">9</SPAN><SPAN style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">月</SPAN><SPAN lang=EN-US style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; FONT-FAMILY: Arial">9</SPAN><SPAN style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">日</SPAN></st1:chsdate><SPAN style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">在线发表于《柳叶刀感染病学》(</SPAN><SPAN lang=EN-US style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; FONT-FAMILY: Arial">Lancet Infectious Diseases</SPAN><SPAN style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">)。</SPAN><SPAN lang=EN-US style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; FONT-FAMILY: Arial"> <?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P> <P style="BACKGROUND: white; LINE-HEIGHT: 16.5pt"><SPAN style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">  </SPAN><SPAN lang=EN-US style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; FONT-FAMILY: Arial">ACT</SPAN><SPAN style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">是恶性疟的一线推荐治疗方案,固定剂量复合制剂则是</SPAN><SPAN lang=EN-US style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; FONT-FAMILY: Arial">WHO</SPAN><SPAN style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">的首选对象。但目前尚不清楚是否应添加单剂杀配子体药伯氨喹。研究者于</SPAN><SPAN lang=EN-US style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; FONT-FAMILY: Arial">2008</SPAN><SPAN style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">年</SPAN><SPAN lang=EN-US style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; FONT-FAMILY: Arial">12</SPAN><SPAN style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">月至</SPAN><SPAN lang=EN-US style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; FONT-FAMILY: Arial">2009</SPAN><SPAN style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">年</SPAN><SPAN lang=EN-US style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; FONT-FAMILY: Arial">3</SPAN><SPAN style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">月在缅甸实施了此项开放标签的随机对照试验,并对</SPAN><SPAN lang=EN-US style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; FONT-FAMILY: Arial">WHO</SPAN><SPAN style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">推荐的</SPAN><SPAN lang=EN-US style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; FONT-FAMILY: Arial">4</SPAN><SPAN style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">种固定剂量</SPAN><SPAN lang=EN-US style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; FONT-FAMILY: Arial">ACT</SPAN><SPAN style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">和可调剂量青蒿琥酯</SPAN><SPAN lang=EN-US style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; FONT-FAMILY: Arial">-</SPAN><SPAN style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">甲氟喹的疗效进行了对比。受试者(年龄</SPAN><SPAN lang=EN-US style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; FONT-FAMILY: Arial">&gt;6</SPAN><SPAN style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">个月,体重</SPAN><SPAN lang=EN-US style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; FONT-FAMILY: Arial">&gt;<st1:chmetcnv w:st="on" TCSC="0" NumberType="1" Negative="False" HasSpace="False" SourceValue="5" UnitName="kg">5Kg</st1:chmetcnv></SPAN><SPAN style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">)均伴有恶性疟原虫感染或混合感染,并被随机分配接受或不接受单剂伯氨喹治疗。随访时间为</SPAN><SPAN lang=EN-US style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; FONT-FAMILY: Arial">63</SPAN><SPAN style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">天。</SPAN><SPAN lang=EN-US style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; FONT-FAMILY: Arial"> <o:p></o:p></SPAN></P> <P style="BACKGROUND: white; LINE-HEIGHT: 16.5pt"><SPAN style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">  接受青蒿琥酯</SPAN><SPAN lang=EN-US style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; FONT-FAMILY: Arial">-</SPAN><SPAN style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">阿莫地喹、青蒿琥酯</SPAN><SPAN lang=EN-US style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; FONT-FAMILY: Arial">-</SPAN><SPAN style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">本芴醇、青蒿琥酯</SPAN><SPAN lang=EN-US style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; FONT-FAMILY: Arial">-</SPAN><SPAN style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">甲氟喹、可调剂量青蒿琥酯</SPAN><SPAN lang=EN-US style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; FONT-FAMILY: Arial">-</SPAN><SPAN style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">甲氟喹和二氢青蒿素</SPAN><SPAN lang=EN-US style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; FONT-FAMILY: Arial">-</SPAN><SPAN style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">哌喹的患者分别为</SPAN><SPAN lang=EN-US style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; FONT-FAMILY: Arial">155</SPAN><SPAN style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">、</SPAN><SPAN lang=EN-US style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; FONT-FAMILY: Arial">162</SPAN><SPAN style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">、</SPAN><SPAN lang=EN-US style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; FONT-FAMILY: Arial">169</SPAN><SPAN style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">、</SPAN><SPAN lang=EN-US style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; FONT-FAMILY: Arial">161</SPAN><SPAN style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">和</SPAN><SPAN lang=EN-US style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; FONT-FAMILY: Arial">161</SPAN><SPAN style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">例。在随访</SPAN><SPAN lang=EN-US style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; FONT-FAMILY: Arial">63</SPAN><SPAN style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">天时,青蒿琥酯</SPAN><SPAN lang=EN-US style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; FONT-FAMILY: Arial">-</SPAN><SPAN style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">阿莫地喹治疗者中有</SPAN><SPAN lang=EN-US style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; FONT-FAMILY: Arial">14</SPAN><SPAN style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">例(</SPAN><SPAN lang=EN-US style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; FONT-FAMILY: Arial">9.4%</SPAN><SPAN style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">)出现复发性恶性疟原虫感染,此比例显著高于接受青蒿琥酯</SPAN><SPAN lang=EN-US style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; FONT-FAMILY: Arial">-</SPAN><SPAN style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">本芴醇(</SPAN><SPAN lang=EN-US style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; FONT-FAMILY: Arial">1.4%</SPAN><SPAN style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">;</SPAN><SPAN lang=EN-US style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; FONT-FAMILY: Arial">P=0.0013</SPAN><SPAN style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">)、固定剂量青蒿琥酯</SPAN><SPAN lang=EN-US style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; FONT-FAMILY: Arial">-</SPAN><SPAN style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">甲氟喹(</SPAN><SPAN lang=EN-US style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; FONT-FAMILY: Arial">0%</SPAN><SPAN style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">;</SPAN><SPAN lang=EN-US style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; FONT-FAMILY: Arial">P&lt;0.0001</SPAN><SPAN style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">)、可调剂量青蒿琥酯</SPAN><SPAN lang=EN-US style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; FONT-FAMILY: Arial">-</SPAN><SPAN style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">甲氟喹(</SPAN><SPAN lang=EN-US style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; FONT-FAMILY: Arial">1.3%</SPAN><SPAN style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">;</SPAN><SPAN lang=EN-US style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; FONT-FAMILY: Arial">P=0.0018</SPAN><SPAN style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">)和二氢青蒿素</SPAN><SPAN lang=EN-US style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; FONT-FAMILY: Arial">-</SPAN><SPAN style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">哌喹(</SPAN><SPAN lang=EN-US style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; FONT-FAMILY: Arial">1.3%</SPAN><SPAN style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">;</SPAN><SPAN lang=EN-US style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; FONT-FAMILY: Arial">P=0.0012</SPAN><SPAN style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">)治疗的患者。</SPAN><SPAN lang=EN-US style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; FONT-FAMILY: Arial"> <o:p></o:p></SPAN></P> <P style="BACKGROUND: white; LINE-HEIGHT: 16.5pt"><SPAN style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">  与两组青蒿琥酯</SPAN><SPAN lang=EN-US style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; FONT-FAMILY: Arial">-</SPAN><SPAN style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">甲氟喹治疗者相比,青蒿琥酯</SPAN><SPAN lang=EN-US style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; FONT-FAMILY: Arial">-</SPAN><SPAN style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">阿莫地喹治疗者的再感染危险比为</SPAN><SPAN lang=EN-US style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; FONT-FAMILY: Arial">3.2</SPAN><SPAN style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">(</SPAN><SPAN lang=EN-US style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; FONT-FAMILY: Arial">P=0.01</SPAN><SPAN style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">);与青蒿琥酯</SPAN><SPAN lang=EN-US style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; FONT-FAMILY: Arial">-</SPAN><SPAN style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">本芴醇治疗者相比为</SPAN><SPAN lang=EN-US style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; FONT-FAMILY: Arial">2.6</SPAN><SPAN style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">(</SPAN><SPAN lang=EN-US style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; FONT-FAMILY: Arial">P=0.04</SPAN><SPAN style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">);与二氢青蒿素</SPAN><SPAN lang=EN-US style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; FONT-FAMILY: Arial">-</SPAN><SPAN style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">哌喹治疗者相比未</SPAN><SPAN lang=EN-US style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; FONT-FAMILY: Arial">2.3</SPAN><SPAN style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">(</SPAN><SPAN lang=EN-US style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; FONT-FAMILY: Arial">P=0.08</SPAN><SPAN style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">)。恶性疟和间日疟混合感染较为常见。添加单剂伯氨喹(</SPAN><SPAN lang=EN-US style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; FONT-FAMILY: Arial">0.75mg/Kg</SPAN><SPAN style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">)可显著减少配子体携带率(</SPAN><SPAN lang=EN-US style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; FONT-FAMILY: Arial">RR=11.9</SPAN><SPAN style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">)。所有疗法的耐受性均较好。</SPAN><SPAN lang=EN-US style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; FONT-FAMILY: Arial">559</SPAN><SPAN style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">例患者出现不良事件,其中呕吐和头晕最为常见。</SPAN><SPAN lang=EN-US style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; FONT-FAMILY: Arial"> <o:p></o:p></SPAN></P> <P style="BACKGROUND: white; LINE-HEIGHT: 16.5pt"><SPAN style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">  述评</SPAN><SPAN style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; FONT-FAMILY: Arial"> </SPAN><SPAN style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">澳大利亚查尔斯达尔文大学普锐斯(</SPAN><SPAN lang=EN-US style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; FONT-FAMILY: Arial">Price</SPAN><SPAN style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">)博士:</SPAN><SPAN lang=EN-US style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; FONT-FAMILY: Arial"> <o:p></o:p></SPAN></P> <P style="BACKGROUND: white; LINE-HEIGHT: 16.5pt"><SPAN style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">  </SPAN><SPAN lang=EN-US style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; FONT-FAMILY: Arial">ACT</SPAN><SPAN style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">已被整合入目前的疟疾治疗策略。其起效迅速,并可完全清除多耐药疟原虫,从而降低传染风险并且限制原发耐药出现。与松散组合的疗法相比,固定剂量</SPAN><SPAN lang=EN-US style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; FONT-FAMILY: Arial">ACT</SPAN><SPAN style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">具有改善治疗依从性以及延长药物使用寿命的潜力,含有甲氟喹、哌喹等长效药物的固定剂量复合制剂则可降低总体复发感染率。</SPAN><SPAN lang=EN-US style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; FONT-FAMILY: Arial"> <o:p></o:p></SPAN></P> <P style="BACKGROUND: white; LINE-HEIGHT: 16.5pt"><SPAN style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">  但同时须看到,亚治疗药物拖尾浓度所导致选择压力有助于耐药疟原虫扩散。青蒿素衍生物对</SPAN><SPAN lang=EN-US style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; FONT-FAMILY: Arial">I</SPAN><SPAN style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">~</SPAN><SPAN lang=EN-US style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; FONT-FAMILY: Arial">III</SPAN><SPAN style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">期配子体具有治疗效果,但对成熟配子体无效。伯氨喹则对各期配子体均有效,并可显著降低恶性疟原虫配子体携带风险。同时亦需注意到单剂伯氨喹有可能诱发溶血,在葡萄糖</SPAN><SPAN lang=EN-US style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; FONT-FAMILY: Arial">-6-</SPAN><SPAN style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">磷酸脱氢酶(</SPAN><SPAN lang=EN-US style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; FONT-FAMILY: Arial">G6PD</SPAN><SPAN style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">)缺乏的患者中尤为明显。</SPAN><SPAN lang=EN-US style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; FONT-FAMILY: Arial"> <o:p></o:p></SPAN></P> <P style="BACKGROUND: white; LINE-HEIGHT: 16.5pt"><SPAN style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">  新闻链接:</SPAN><SPAN lang=EN-US style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; FONT-FAMILY: Arial"><A href="http://www.thelancet.com/journals/laninf/article/PIIS1473-3099(10)70187-0/abstract" target=_blank>Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open-label randomised trial </A>&nbsp;<o:p></o:p></SPAN></P>
返回>>>
浙江省医院药事管理质控中心网 版权所有@2008 All Right Reserved。 浙江省医院药事管理质控中心主办
地址:杭州市庆春路79号(310003)        Email:zhejiangyszk@163.com
建议浏览器IE6.0+ 分辨率:1024*768以上